Advanced search
Publication Cover
Clinical Ophthalmology Volume 18, 2024 - Issue
Submit an article Journal homepage
48
Views
0
CrossRef citations to date
0
Altmetric
CLINICAL TRIAL REPORT

Improved Signs and Symptoms of Dry Eye Disease for Restasis® Patients Following a Single Tearcare® Treatment: Phase 2 of the SAHARA Study

Brandon D Ayres1 Private Practice, Philadelphia, PA, USA
,
Marc R Bloomenstein2 Schwartz Laser Eye Center, Scottsdale, AZ, USA
,
Jennifer Loh3 Loh Ophthalmology Associates, Miami, FL, USA
,
Thomas Chester4 Cleveland Eye Clinic, Brecksville, OH, USA
,
Bobby Saenz5 Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, TX, USA;6 LASIK San Antonio, Kerrville, TX, USAORCID Iconhttps://orcid.org/0000-0001-6961-1836
ORCID Icon,
Julio Echegoyen7 Gordon Schanzlin New Vision Institute, La Jolla, CA, USA
,
Shane R Kannarr8 Kannarr Eye Care, Pittsburg, KS, USA
,
Tomasita C Rodriguez9 Sight Sciences, Menlo Park, CA, USA
&
Jaime E Dickerson Jr9 Sight Sciences, Menlo Park, CA, USA;10 North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6748-9742
ORCID Icon show all
Pages 1525-1534 | Received 16 Feb 2024, Accepted 22 May 2024, Published online: 30 May 2024

References

  • Farrand KF, Fridman M, Stillman I, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90–98. doi:10.1016/j.ajo.2017.06.033
  • Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334–365. doi:10.1016/j.jtos.2017.05.003
  • Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922–1929. doi:10.1167/iovs.10-6997a
  • Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472–478. doi:10.1097/ICO.0b013e318225415a
  • Tong L, Chaurasia SS, Mehta JS, Beuerman RW. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore. Invest Ophthalmol Vis Sci. 2010;51(7):3449–3454. doi:10.1167/iovs.09-4445
  • Viso E, Gude F, Rodríguez-Ares MT. The association of meibomian gland dysfunction and other common ocular diseases with dry eye: a population-based study in Spain. Cornea. 2011;30(1):1–6. doi:10.1097/ICO.0b013e3181da5778
  • Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4):2050–2064. doi:10.1167/iovs.10-6997g
  • Ayres BD, Bloomenstein MR, Loh J, et al. A randomized, controlled trial comparing tearcare® and cyclosporine ophthalmic emulsion for the treatment of dry eye disease (SAHARA). Clin Ophthalmol. 2023;17:3925–3940. doi:10.2147/OPTH.S442971
  • Korb DR, Blackie CA. Meibomian gland diagnostic expressibility: correlation with dry eye symptoms and gland location. Cornea. 2008;27(10):1142–1147. doi:10.1097/ICO.0b013e3181814cff
  • Gupta PK, Holland EJ, Hovanesian J, et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea. 2022;41:417–426. doi:10.1097/ICO.0000000000002837
  • Badawi D. A novel system, TearCare, for the treatment of the signs and symptoms of dry eye disease. Clin Ophthalmol. 2018;12:683–694. doi:10.2147/OPTH.S160403
  • Williams DL. A comparative approach to topical cyclosporine therapy. Eye. 1997;11(4):453–464. doi:10.1038/eye.1997.126
  • Miller KL, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010;128(1):94–101. doi:10.1001/archophthalmol.2009.356
  • Badawi D. TearCare system extension study: evaluation of the safety, effectiveness, and durability through 12 months of a second TearCare treatment on subjects with dry eye disease. Clin Ophthalmol. 2019;13:189–198. doi:10.2147/OPTH.S191588
  • Karpecki P, Wirta D, Osmanovic S, Dhamdhere K. A prospective, post-market, multicenter trial (CHEETAH) suggested tearcare system as a safe and effective blink-assisted eyelid device for the treatment of dry eye disease. Clin Ophthalmol. 2020;14:4551–4559. doi:10.2147/OPTH.S285953
  • Chester T. A single-center retrospective trial of a blink-assisted eyelid device in treating the signs and symptoms of dry eye. Optom Vis Sci. 2021;98(6):605–612. doi:10.1097/OPX.0000000000001711

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.